Liquid Biopsy Market

Liquid Biopsy Market Research, 2034

Liquid Biopsy Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15.3% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 5.1 billion and is projected to reach USD 24.7 billion by the completion of 2034.

Liquid biopsy is a non-invasive diagnostic test that identifies disease indicators in bodily fluids, such as blood. It is particularly useful in detecting genetic and molecular alterations, especially in cancer. Unlike traditional biopsies that require surgical procedures to obtain tissue samples, liquid biopsies involve a simple blood test or fluid sample collection, making the process less invasive and more accessible. Liquid biopsy is utilized for early cancer detection, monitoring treatment response, tracking disease progression, and identifying minimal residual disease and relapse. Techniques like Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Digital Droplet PCR are employed to detect and analyze genetic mutations, chromosomal abnormalities, and disease biomarkers. Beyond cancer, liquid biopsy is also used to test for genetic defects in unborn babies, monitor organ transplant rejection, and is becoming applicable in heart, infection-related, and immune system disorders.

Market Highlights

Liquid Biopsy Market is anticipated to grow at a robust rate, with projections indicating a 15.3% compound annual growth rate (CAGR) between 2024 and 2034

Liquid Biopsy Market is expected to reach USD 24.7 billion during the forecast period, driven by the increasing demand for non-invasive diagnostics. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, thus increasing its use for various diagnostic purposes. As global cancer cases continue to rise, there is a growing need for tools that can detect and monitor the disease in its early stages, leading to a higher demand for liquid biopsies. Additionally, advancements in technologies such as PCR, NGS, and Digital Droplet PCR enhance the precision and sensitivity of liquid biopsies, further fueling market growth. New technological advancements are also making liquid biopsies more accurate and affordable, making them more accessible to healthcare providers and patients.

Liquid Biopsy Market Segmentation

Kits & Reagents segment is anticipated to lead owing to its critical role in the diagnostic process and widespread use

Liquid Biopsy Market is segmented based on Product into Services, Kits & Reagents, and Platforms & Instruments. The Kits & Reagents segment is anticipated to lead the market due to its critical role in the diagnostic process and widespread use. Kits and reagents are essential for sample preparation, biomarker discovery, and result analysis, which are crucial for the test. The demand for more advanced kits and reagents is driven by the need for precise and reliable results. Continuous enhancements in these products increase diagnostic accuracy, further strengthening their importance in the market. Kits and reagents are utilized in various diagnostic procedures, including cancer detection, prenatal testing, and organ transplantation, contributing to market expansion. Technological advancements in kits and reagents also improve the efficiency of liquid biopsies, enhancing their market presence.

Next-Generation Sequencing (NGS) segment will dominate the industry due to its ability to analyze a wide range of genetic mutations and alterations

Liquid Biopsy Market is classified based on Technology into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cytometry, and Digital PCR. The Next-Generation Sequencing segment is expected to dominate the Liquid Biopsy Market due to its ability to analyze a wide range of genetic mutations and alterations. NGS enables comprehensive tumor evaluation and the development of customized treatment strategies by accurately identifying various genetic alterations with high sensitivity and precision. Liquid biopsy using NGS is less invasive compared to traditional tissue biopsies. Continuous advancements in NGS technology further enhance its efficiency, positioning it as a preferred option for comprehensive liquid biopsy analysis..

Market Dynamics

Growth Drivers

Increasing Cancer Incidence is Critical to Boost the Adoption of Liquid Biopsy

Increasing number of cancer cases significantly boosts the liquid biopsy market. With the growing demand for early detection methods, liquid biopsies have gained popularity as a non-invasive way to detect cancer at an early stage. As cancer rates rise, patients require more frequent monitoring, and liquid biopsies provide a simpler way to track disease progression and treatment effectiveness. Liquid biopsies also offer detailed genetic information, aiding in the development of personalized treatment plans for cancer management. The increased need for efficient early detection, monitoring, and customized treatment drives the demand for liquid biopsy solutions, contributing to market growth.

Advancements in Technology Will Ai the Market

Technological advancements are propelling the expansion of the liquid biopsy market. Recent innovations enable the identification of a broader range of biomarkers, expanding the potential applications of liquid biopsies to various cancer types and other health conditions. The accuracy of liquid biopsies in detecting genetic changes and biomarkers is enhanced by new technologies, leading to increased utilization. Additionally, technological advancements have made liquid biopsies more efficient in clinical settings, providing faster testing and quicker results. Furthermore, advancements in technology are reducing the cost of liquid biopsy tests, making them more accessible and affordable for a broader range of healthcare providers and patients.

Restraints

High Costs Can Limit the Growth of the Liquid Biopsy Market

High costs associated with liquid biopsy tests are a significant barrier to market growth. These tests can be expensive, making them less accessible to patients, particularly those without adequate insurance coverage or in low-income regions. The high cost limits the market's expansion as hospitals and clinics, often operating under budget constraints, may prefer less expensive conventional diagnostic methods over costly liquid biopsy technologies. Additionally, the high expenses associated with liquid biopsies can limit research and development efforts, making it challenging for smaller companies and institutions to invest in the necessary technologies and resources. As a result, patients and healthcare providers may opt for traditional diagnostic methods, further impeding market growth.

Recent Developments

• Guardant Health, Inc. introduced the Guardant Reveal™ liquid biopsy test in 2024 to improve early-stage cancer detection through more accurate identification of minimal residual disease and assessment of treatment response.
• In 2024, Natera, Inc. upgraded the Signatera™ test with additional functions to enhance sensitivity and specificity for cancer monitoring, integrating advanced analytics for improved disease progression and treatment efficacy monitoring.
• In 2023, Roche Holding AG broadened its range of products by launching the "Cobas LiquidBiopsy" test for lung cancer, aimed at improving the identification and tracking of mutations in lung cancer patients.
• In 2022, Exosome Diagnostics, Inc. launched a fresh liquid biopsy system for tracking prostate cancer. It utilizes exosome examination to offer information on the advancement of the disease and the reaction to treatment.

Key Players:

• Guardant Health, Inc.
• QIAGEN N.V.
• Natera, Inc.
• Singular Genomics Systems, Inc.
• Exosome Diagnostics, Inc.
• Illumina, Inc.
• Asuragen, Inc.
• MDxHealth SA
• Thermo Fisher Scientific Inc.
• Epigenomics AG
• Sysmex Corporation
• Circulating Cell-Free Genome Atlas (CCGA)
• Foundation Medicine, Inc.
• Biocept, Inc.
• Roche Holding AG
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Liquid Biopsy Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American region is anticipated to dominate the Liquid Biopsy Market as the region has a mature healthcare system that enables the use of cutting-edge medical innovations such as liquid biopsy. Also, the high incidence of cancer in North America is driving the need for efficient tools for diagnosis and monitoring. Moreover, North America is home to numerous leading biotech and pharmaceutical firms that invest heavily in creating new diagnostic techniques, such as liquid biopsy, resulting in market growth in this region. Additionally, healthcare providers and patients in this area have a greater understanding and willingness to use advanced diagnostic methods. Furthermore, positive reimbursement policies in nations such as the US drive the uptake of liquid biopsy technologies.

Impact of COVID-19 on the Liquid Biopsy Market

COVID-19 pandemic had a dual impact on the Liquid Biopsy Market. The supply chain for reagents, equipment, and other necessary components for liquid biopsy testing was disrupted by the pandemic, affecting the manufacturing and accessibility of liquid biopsy kits and services. Many clinical trials were delayed or canceled, impacting the progress and testing of emerging liquid biopsy technologies. However, the demand for non-invasive tests increased during the pandemic in order to minimize patient visits to healthcare facilities, which potentially led to a rise in the utilization of liquid biopsies. Additionally, the expansion of telehealth has simplified the process of remote consultations and monitoring, potentially increasing the utilization of liquid biopsies for continuous patient care.

Liquid Biopsy Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Liquid Biopsy Market Scope and Segments:

Frequently Asked Questions (FAQ):